Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Daiichi Sankyo Inc.

Division of Daiichi Sankyo Co. Ltd.
www.dsi.com

Latest From Daiichi Sankyo Inc.

Opioid Blister Packs Need Study Before Mandate, Groups Urge

AAM, Upsher-Smith, APhA, and Cigna tell US FDA that packaging requirement will increase manufacturing and drug costs, create reimbursement hurdles and reduce access to medicines. Daiichi-Sankyo supports agency's proposal.

Drug Safety Neurology

EOC Gears To Evolve Into Integrated Oncology Company

Oncology focused startup EOC Pharma expects to develop an “exciting” pipeline in two years via the licensing model. The company is also seeking “constant” financing as it advances three drug candidates into the next stage in 2018, EOC CEO Xiaoming Zou tells Scrip in an interview.

BioPharmaceutical China

Amgen & Simcere Plot Long Run On Biosimilars In China

The strategic alliance between Amgen and Simcere Pharmaceutical to develop biosimilars in China was officially kicked off in Nanjing city last week, amid heightened excitement around China’s newly issued opinions on deepening reforms to encourage drug innovation including biosimilars. With the favorable opportunities, Amgen is open to establishing more local partnerships as its core China strategy.

China Biosimilars

Amgen & Simcere Plot Long Run On Biosimilars In China

The strategic alliance between Amgen and Simcere Pharmaceutical to develop biosimilars in China was officially kicked off in Nanjing city last week, amid heightened excitement around China’s newly issued opinions on deepening reforms to encourage drug innovation including biosimilars. With the favorable opportunities, Amgen is open to establishing more local partnerships as its core China strategy.

China Biosimilars
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Cardiovascular
  • Musculoskeletal & Connective Tissue Disorders
  • Alias(es)
  • Sankyo Pharma Inc.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Daiichi Sankyo Co. Ltd.
  • Senior Management
  • Glenn Gormley, MD, PhD, Chmn. & Pres.
    Ken Keller, Pres., US Commercial
    Marielle Cohard-Radice, MD, EVP, Global Head, Dev.
  • Contact Info
  • Daiichi Sankyo Inc.
    Phone: (973) 359-2600
    2 Hilton Ct.
    Parsippany, NJ 07054
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register